<DOC>
	<DOCNO>NCT00870714</DOCNO>
	<brief_summary>Eligible patient high-risk prostate cancer schedule undergo radical prostatectomy receive four cycle therapy ketoconazole docetaxel prior surgery resection . A cycle therapy define 21 day ( three week ) . Pharmacokinetic analysis perform first second cycle therapy . All patient evaluate toxicity , tumor response , recurrence .</brief_summary>
	<brief_title>Neoadjuvant Therapy With Docetaxel Ketoconazole Patients With High-Risk Prostate Cancer : A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Patients must histologically prove adenocarcinoma prostate . Patients must meet least one follow high risk criterion : PSA &gt; 20 Gleason score 8 great Presence pathological Gleason grade 4 high majority sum biopsy core Greater 50 % core time biopsy positive cancer Clinical Stage T3 Disease Patients must PS 01 ( ECOG ) medically deem surgical candidate radical prostatectomy . Age &gt; = 18 . Patients preexist peripheral neuropathy equal great grade two ineligible . Serum Creatinine must &lt; equal 2.0mg/dl . Patients must currently receive drug metabolize cytochrome P4503A4 include statin , cyclosporin , terfenadine erythromycin . Prior receive dose docetaxel , patient absolute neutrophil count &gt; 1,500 , hemoglobin &gt; 8.0 g/dl platelet count &gt; 100,000/mm3 . Patients bilirubin elevate institutional upper limit normal ( ULN ) must exclude . Transaminases ( SGOT and/or SGPT ) may 5.0 x institutional upper limit normal ( ULN ) alkaline phosphatase &lt; ULN , alkaline phosphatase may 5 x ULN transaminases &lt; ULN . However , patient transaminase elevation &gt; 1.5 x ULN alkaline phosphatase &gt; 2.5 x ULN eligible study ( due decrease clearance docetaxel increase risk toxicity ) . Patients receive concurrent warfarin eligible require monitoring protime weekly basis . Patients clinical stage T4 disease eligible . Patients must receive prior treatment surgery , radiation hormone deprivation . Patients primary malignancy previously treat chemotherapeutic agent eligible . Patients must history peptic ulcer disease require treatment surgery endoscleral . Patients require corticosteroid systemic disease eligible . Patients history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 eligible . All patient must sign informed consent . Men childbearing potential must willing consent use effective contraception treatment least 3 month thereafter .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>